Related Experiment Video
Updated: Dec 31, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Use of triptans during pregnancy? With caution!
Isabelle Lacroix1, Caroline Hurault-Delarue1, Delphine Viard2
1Service de pharmacologie médicale et clinique, centre régional de pharmacovigilance, faculté de médecine, Inserm 1027, 31000 Toulouse, France.
Pregnancy exposure to triptans, used for migraines, is linked to fetal death and growth issues. Careful risk-benefit assessment is crucial for these vasoconstrictive medications during pregnancy.
Area of Science:
- Pharmacovigilance
- Obstetrics
- Neurology
Background:
- Triptans are commonly prescribed for migraine treatment.
- Potential risks associated with triptan use during pregnancy are not fully understood.
Discussion:
- This report details cases of fetal death and intrauterine growth retardation (IUGR) in pregnant women exposed to triptans.
- The vasoconstrictive properties of triptans raise concerns about their potential role in these adverse pregnancy outcomes.
Key Insights:
- A causal link between triptan use and adverse fetal outcomes requires further investigation.
- The French national pharmacovigilance database documented these concerning cases.
Outlook:
- Further research is needed to establish the safety profile of triptans in pregnancy.
- Clinicians must carefully weigh the benefits and risks of prescribing triptans to pregnant patients.
More Related Videos
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Radiological Investigation I: X-ray and CT
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Mitral Valve Prolapse III: Nursing Management
Teratogenicity
Adrenergic Antagonists: ɑ and β-Receptor Blockers

